Lakewood-Amedex Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lakewood-Amedex Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11273
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lakewood-Amedex Inc (Lakewood-Amedex) is a clinical-stage pharmaceutical company with focus on the development of antimicrobial and antifungal medicines to address unmet needs in the treatment of serious infectious diseases. The company develops anti-infective products such as anti-bacterial compounds, gene-silencing antivirals, locally delivered and orally available nanoRNA therapeutics. Its antimicrobial product pipeline includes Nu-3, small protonated nucleotide derivative molecules used for the treatment of complicated diabetic foot ulcers (cDFU); Nu-8, is intended to treat complicated urinary tract infections (cUTI) and Cystic Fibrosis. The company works in partnership with other biopharmaceutical companies, animal health companies, and academic and government institutions. Lakewood-Amedex is headquartered in Sarasota, Florida, the US.

Lakewood-Amedex Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Lakewood-Amedex Raises USD1 Million in Venture Financing 10
Lakewood-Amedex Raises USD5.5 Million in Series C Financing 11
Partnerships 12
Lakewood-Amedex Expands Research Agreement with University of Jyvaskyla 12
Lakewood-Amedex Enters into Co-Development Agreement with Ethicor Pharma 13
Lakewood-Amedex Inc – Key Competitors 14
Lakewood-Amedex Inc – Key Employees 15
Lakewood-Amedex Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
May 11, 2018: Lakewood-Amedex Elects Stephen Evans-Freke as New Chairman of the Board of Directors 17
Product News 18
11/28/2017: Lakewood-Amedex to Present at the 10th Annual LD Micro Main Event 18
09/27/2017: Lakewood-Amedex Reports Positive Top-Line Data from Randomized Controlled Phase 1/2a Trial of Nu-3 Antimicrobial in Patients with Infected Diabetic Foot Ulcers 19
08/31/2017: Lakewood-Amedex Strengthens Board of Directors with Two Industry Veterans 20
08/22/2017: Lakewood-Amedex Completes Clinical Trial Recruitment for Final Cohort of the Companys Phase 1/2a Program in Patients with Infected Diabetic Foot Ulcers 21
02/08/2018: Lakewood-Amedex to Present Clinical Update on Nu-3 at 2018 BIO CEO & Investor Conference 22
02/08/2018: Lakewood-Amedex to Present Pre-Clinical Update on Nu-8 at 2018 BIO CEO & Investor Conference 23
Clinical Trials 24
Dec 04, 2017: Lakewood-Amedex Advances Bisphosphocin Nu-8 to IND-Enabling Studies to Treat Complicated Urinary Tract Infection 24
Apr 04, 2017: Lakewood-Amedex Advances Novel Bisphosphocin Nu-8 Compound Based on Encouraging Pre-Clinical Results 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Key Facts 2
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lakewood-Amedex Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lakewood-Amedex Raises USD1 Million in Venture Financing 10
Lakewood-Amedex Raises USD5.5 Million in Series C Financing 11
Lakewood-Amedex Expands Research Agreement with University of Jyvaskyla 12
Lakewood-Amedex Enters into Co-Development Agreement with Ethicor Pharma 13
Lakewood-Amedex Inc, Key Competitors 14
Lakewood-Amedex Inc, Key Employees 15

List of Figures
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lakewood-Amedex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lakewood-Amedex Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Syndax Pharmaceuticals Inc (SNDX):企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • HUK-COBURG-Versicherungsgruppe:企業の戦略・SWOT・財務情報
    HUK-COBURG-Versicherungsgruppe - Strategy, SWOT and Corporate Finance Report Summary HUK-COBURG-Versicherungsgruppe - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Gildan Activewear Inc.:企業の戦略・SWOT・財務情報
    Gildan Activewear Inc. - Strategy, SWOT and Corporate Finance Report Summary Gildan Activewear Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Axela Inc:製品パイプライン分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • Fresenius Kabi AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and …
  • Murphy Oil Corp (MUR):企業の財務・戦略的SWOT分析
    Murphy Oil Corp (MUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Oxford Biodynamics Plc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • Obton AS:電力:M&Aディール及び事業提携情報
    Summary Obton A/S (Obton) is an investment company that offers management of assets within renewable energy. The company's investment process include screening process which inludes verification of prerequisites such as financial terms, amount of irradiation, power purchase agreement and feed-in tar …
  • Kuwait Petroleum International Ltd:企業の戦略的SWOT分析
    Kuwait Petroleum International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bill & Melinda Gates Foundation:企業のM&A・事業提携・投資動向
    Bill & Melinda Gates Foundation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bill & Melinda Gates Foundation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Eastman Kodak Company:戦略・SWOT・企業財務分析
    Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report Summary Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報
    Summary Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers medicines for the treatment of cancer, infectious diseases such as HIV, multiple sclerosis and immuno …
  • Navitas Ltd:企業の戦略的SWOT分析
    Navitas Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Vornado Realty Trust:企業の戦略・SWOT・財務分析
    Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report Summary Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Southern Company Gas:企業の戦略的SWOT分析
    Southern Company Gas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Aclara Technologies LLC-エネルギー分野:企業M&A・提携分析
    Summary Aclara Technologies LLC (Aclara), as a subsidiary of Sun Capital Partners, Inc. The company designs, develops and commercializes Advanced Metering Infrastructure (AMI) solutions for data value management, customer communication and device networking activities. It provides an array of custom …
  • Green Cross LabCell Corp (144510):製薬・医療:M&Aディール及び事業提携情報
    Summary Green Cross LabCell Corp (GCLabCell), a subsidiary of GC Pharma, is a biotechnology company that offers biopharmaceuticals. The company’s products include specialty medicines, blood products and vaccines, generic drugs, parenteral products, and genetically-modified hemophilia A drug Greenjun …
  • Nymox Pharmaceutical Corp (NYMX):企業の財務・戦略的SWOT分析
    Nymox Pharmaceutical Corp (NYMX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Fintel Energia Group SpA (FTL):企業の財務・戦略的SWOT分析
    Summary Fintel Energia Group SpA (Fintel) is a utility service provider that supplies electricity and natural gas. The company's services include designing, consultation, and installation of technologies and system of production of renewable energies for the Group and to third parties. It also provi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆